Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Corynebacterium diphtheriae

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Corynebacterium diphtheriae. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2014-001119-38 Sponsor Protocol Number: 116945 Start Date*: 2015-09-21
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women.
    Medical condition: Booster immunisation against diphtheria, tetanus and pertussis diseases. The study population for this study will include pregnant women.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10047976 Whooping cough due to bordetella pertussis (B. pertussis) LLT
    18.0 100000004862 10009663 Clostridium tetani infection LLT
    18.0 100000004862 10054237 Corynebacterium diphtheriae infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) CZ (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000195-13 Sponsor Protocol Number: V59P5 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase II, Randomized, Open label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory after Two or Three Doses of Novartis Meningococcal ACW...
    Medical condition: Prevention of invasive disease caused by Neisseria Meningitidis serogroup A, C, W-135 and Y
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006124-64 Sponsor Protocol Number: 111815 (DTPA-IPV(BOOSTRIX-IPV)-010 Start Date*: 2009-02-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with S...
    Medical condition: Booster immunisation of healthy preschool children against diphtheria, tetanus, pertussis, poliomyelitis, mumps, measles and rubella; and first or second immunisation of healthy preschool children ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034738 LLT
    9.1 10013023 LLT
    9.1 10043376 LLT
    9.1 10036012 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004741-37 Sponsor Protocol Number: 212458 Start Date*: 2021-06-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt...
    Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000943-26 Sponsor Protocol Number: 115375 Start Date*: 2011-05-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV...
    Medical condition: Healthy volunteers (Immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Hib vacc...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2021-001367-24 Sponsor Protocol Number: 217043 Start Date*: 2021-11-16
    Sponsor Name:GlaxoSmithKline SA
    Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.
    Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Completed) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001896-21 Sponsor Protocol Number: V59P7 Start Date*: 2004-11-03
    Sponsor Name:Chiron S.r.l.
    Full Title: A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59...
    Medical condition: Prevention of invasive disease caused by Neisseria Meningitidis serogroup A, C, W-135 and Y
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-004982-42 Sponsor Protocol Number: 213171 Start Date*: 2021-02-08
    Sponsor Name:GlaxoSmithKline Biologics SA (GSK)
    Full Title: A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously...
    Medical condition: Healthy volunteers (active immunization against invasive disease caused by N. meningitidis serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012219-16 Sponsor Protocol Number: 113060 Start Date*: 2011-04-18
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and reactogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, ...
    Medical condition: Booster immunisation of healthy adults against diphtheria, tetanus, pertussis and poliomyelitis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004056-36 Sponsor Protocol Number: Sched2 Start Date*: 2007-12-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses ...
    Medical condition: All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against: Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027274 Meningococcal infection PT
    9.1 10061353 Pneumococcal infection LLT
    9.1 10013023 Diphtheria LLT
    9.1 10043376 Tetanus LLT
    9.1 10034738 Pertussis LLT
    9.1 10018955 Haemophilus meningitis LLT
    9.1 10036008 Polio LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003456-23 Sponsor Protocol Number: 207467 Start Date*: 2018-05-30
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 2b, randomized, controlled, observer-blind, multi-center study to evaluate safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3...
    Medical condition: Prophylaxis against bacterial meningitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed) ES (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016635-36 Sponsor Protocol Number: 113615 Start Date*: 2010-03-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2,...
    Medical condition: Primary and booster immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, serogroup C meningoc...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043376 Tetanus LLT
    12.1 10013023 Diphtheria LLT
    12.1 10034738 Pertussis LLT
    12.1 10019731 Hepatitis B LLT
    12.1 10036012 Poliomyelitis LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10027274 Meningococcal infection LLT
    12.1 10067470 Rotavirus infection LLT
    12.1 10061353 Pneumococcal infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000979-27 Sponsor Protocol Number: V102_16 Start Date*: 2015-05-07
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolesc...
    Medical condition: Prophylaxis against invasive disease strains of N. meningitidis serogroup B.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012460-14 Sponsor Protocol Number: 112980 Start Date*: 2010-05-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paed...
    Medical condition: Primary and booster immunisation of healthy infants in the first two years of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, rotavirus and p...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043376 Tetanus LLT
    12.1 10013023 Diphtheria LLT
    12.1 10034738 Pertussis LLT
    12.1 10019731 Hepatitis B LLT
    12.1 10036012 Poliomyelitis LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10067470 Rotavirus infection LLT
    12.1 10061353 Pneumococcal infection LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) GB (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001666-15 Sponsor Protocol Number: 205416 Start Date*: 2020-08-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to hea...
    Medical condition: Healthy volunteers (Active immunization against invasive disease caused by N. meningitidis serogroups A, B, C, W and Y)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) EE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001670-33 Sponsor Protocol Number: 215344 Start Date*: 2022-02-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
    Medical condition: Healthy volunteers (Active immunization against IMD caused by N.meningitidis serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000876-33 Sponsor Protocol Number: 114843 Start Date*: 2011-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in heal...
    Medical condition: Healthy volunteers (toddlers): Booster immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021569-58 Sponsor Protocol Number: 113948 Start Date*: 2010-11-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to...
    Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-004313-13 Sponsor Protocol Number: C3511001 Start Date*: 2020-08-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10076061 Meningococcal immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003937-41 Sponsor Protocol Number: V102_03E1 Start Date*: 2014-01-17
    Sponsor Name:GSK Vaccines S.r.l
    Full Title: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Follow...
    Medical condition: This study will evaluate the safety and immunogenicity of a booster dose of MenABCWY vaccine; either MenABCWY+OMV or MenABCWY+1/4OMV, administered to adolescent and young adults who previously rece...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:22:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA